Skip to main content

Table 1 Comparison of clinical and laboratory characteristics between patients with and without PMI

From: Impact of multi-vessel therapy to the risk of periprocedural myocardial injury after elective coronary intervention: exploratory study

 

Non-PMI (n = 333)

PMI (n = 211)

P

Clinical characteristics

   

 Male (%)

231 (69.4%)

147 (69.6%)

0.941

 Age (year)

62.9 ± 9.1

66.4 ± 9.3

<0.01

 Hypertension (%)

215 (64.6%)

151 (71.6%)

0.090

 Hyperlipidemia (%)

102 (30.6%)

71 (33.6%)

0.674

 Diabetes (%)

73 (22.0%)

64 (30.3%)

0.028

 Smoking (%)

140 (41.4%)

73 (34.6%)

0.088

 LVEF (%)

62.4 ± 6.7

60.3 ± 5.8

0.542

 Systolic blood pressure (mmHg)

127.8 ± 13.8

133.2 ± 15.9

0.105

 Diastolic blood pressure (mmHg)

76.3 ± 8.3

75.2 ± 8.1

0.544

 Heart rate (beat per minute)

69 ± 11

70 ± 8

0.802

Laboratory characteristics

   

 eGFR (ml/min)

94.4 ± 20.4

92.6 ± 22.6

0.486

 Total cholesterol (mmol/L)

3.98 ± 1.02

4.26 ± 1.44

0.018

 Triglyceride (mmol/L)

1.85 ± 0.96

2.04 ± 1.89

0.102

 Pre-procedural CK-MB (U/L)

12.4 ± 5.8

13.9 ± 4.7

0.584

 Post-procedural CK-MB (U/L)

18.5 ± 10.4

14.2 ± 5.6

0.054

 Pre-procedure troponin T (ng/ml)

0.014 ± 0.018

0.016 ± 0.017

0.872

 Post-procedure troponin T (ng/ml)

0.015 ± 0.021

0.156 ± 0.291

<0.01

Medication before angiography

   

 Beta-blocker (%)

273 (82.0)

177 (83.9)

0.794

 ACEI/ARB (%)

229 (68.8)

137 (64.9)

0.588

 Aspirin (%)

301 (90.4)

184 (87.2)

0.536

 Statin (%)

314 (94.3)

200 (94.8)

0.921

  1. Abbreviations: ACEI/ARBs angiotensin-converting enzyme inhibitors/angiotensin receptor blocker, CK creatine kinase, eGFR estimated glomerular filtration rate, LVEF left ventricular ejection fraction, PMI Periprocedural myocardial injury